TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00926965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: amisulpride tablet 100-1200mg/day for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine tablet 2.5 to 30 mg/day for 24 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antipsychotics
Description: the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
Study: NCT04579393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fostamatinib
Description: The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
Study: NCT04449432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROWell (Interactive Obesity Treatment Approach)
Description: Personalized messaging via cell phone to support healthy eating behaviors during pregnancy and through 6 months postpartum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Support Control
Description: Personalized messaging via cell phone to support healthy behaviors during pregnancy and through 6 months postpartum
Study: NCT02936154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02682498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (Bupivacaine Liposome Injectable Suspension)
Description: Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
Study: NCT04316767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Intervention
Description: Participants will receive access to a self-care app for use on their smartphone. The app provides a suite of tools based on cognitive behavioral therapy and mindfulness. The app guides users through a variety of short lessons (3-5 minutes) that teach users to self-manage stress, mood, anxiety, and depression. Participants will be encouraged to use the app on a daily basis and will be able to use the app at their discretion.
Study: NCT00242463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone (anabolic steroid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04594434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scale SUD
Description: Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale SUD
Description: Subjective Units of Distress Scale ou Subjective Units of Disturbance Scale is a scale of subjective appreciation of emotions
Study: NCT03317210

Intervention type: DRUG
Group type: OTHER
Intervention: iron sucrose (200 mg VENOFER®)
Description: According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.

Intervention type: DRUG
Group type: OTHER
Intervention: iron sucrose (200 mg VENOFER®)
Description: According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.

Intervention type: DRUG
Group type: OTHER
Intervention: iron sucrose (200 mg VENOFER®)
Description: According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.

Intervention type: DRUG
Group type: OTHER
Intervention: recombinant human erythropoietin (10,000 U EPREX®)
Description: According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.

Intervention type: DRUG
Group type: OTHER
Intervention: recombinant human erythropoietin (10,000 U EPREX®)
Description: According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
Study: NCT02453087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDS0780A
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDS0780A
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCDS0780A
Description: Participants will receive escalating doses of DCDS0780A as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
Study: NCT04594434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOC scale
Description: The VOC (Validity Of Cognition) scale is a scale of value given to cognition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOC scale
Description: The VOC (Validity Of Cognition) scale is a scale of value given to cognition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DES II scale
Description: The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DES II scale
Description: The Dissociative Experiences Scale (DES), which is translated as the Dissociative Experiences Scale, is a self-questionnaire to assess the frequency of various dissociative symptoms in the patient's daily life.
Study: NCT00469898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~\*up to 6 cycles at physician's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes.
Study: NCT03499873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3% Oph Susp
Description: Nepafenac 0.3% Ophthalmic suspension (experimental product)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.3% Oph Susp (reference)
Description: Nepafenac 0.3% Ophthalmic suspension (Innovator)
Study: NCT01055834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Description: Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg
Description: Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug.
Study: NCT00728754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant Osseotite Prevail
Description: Root form titanium dental implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant Osseotite
Description: root form titanium dental implant
Study: NCT04021511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OAR application by a nurse
Description: As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
Study: NCT02654145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100mg SC
Description: At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol MDIs
Description: Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
Study: NCT02253329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein plus NMES during the day
Description: Neuromuscular electrical stimulation after a protein bolus, performed during the day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dietary protein plus NMES prior to sleep
Description: Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
Study: NCT02856594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02325232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy, double balloon enteroscopy sequential use
Description: Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
Study: NCT00872469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1-2 grams by intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [Saline]
Description: Matched to active comparator
Study: NCT01349907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study: NCT02269319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-I
Description: Oral MRX-I 800mg given twice a day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Oral linezolid 600mg given twice a day for 10 days
Study: NCT02665962

Intervention type: OTHER
Group type: OTHER
Intervention: Perioperative Caloric Restriction Program
Study: NCT02120872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin and simvastatin
Description: Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Platelet rich fibrin
Description: Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Flap Debridement alone
Description: Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
Study: NCT01930643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS
Description: HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
Study: NCT00590993

Intervention type: OTHER
Intervention: MRI and MRSI
Description: Compare treatment impact when using MRI and MRSI
Study: NCT01581879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone HCL Capsules, 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone Hydrochloride
Description: Ziprasidone HCL Capsules, 20 mg
Study: NCT01426906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
Study: NCT03405662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vielight Neuro Gamma
Description: The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Vielight Neuro Gamma
Description: The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
Study: NCT03383185

Intervention type: DEVICE
Intervention: Intrauterine device
Description: Use of Intrauterine device during the follow-up period

Intervention type: DRUG
Intervention: Combined Oral Contraceptive
Description: Use of combined oral contraceptive during the follow-up period

Intervention type: DRUG
Intervention: Progestin-only pills
Description: Use of progestin-only pills during the follow-up period

Intervention type: DRUG
Intervention: Depot-Medroxyprogestereone Acetate
Description: Use of depot-medroxyprogesterone acetato during the follow-up period
Study: NCT00432575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surinabant (SR147778)
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surinabant (SR147778)
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surinabant (SR147778)
Description: oral administration
Study: NCT03735498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Description: Promote effective coping and reduce caregiving burden
Study: NCT03773653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT to be combined with BAT
Description: Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT to be combined with MT
Description: Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMT to be combined with IOT
Description: Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
Study: NCT04566731

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. The current, 1.5 mA, is approximately of the same intensity as the current provided by a 9-volt battery. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: tDCS is a type of non-invasive brain stimulation in which small electrical currents are applied to the scalp via 2 electrodes. During sham stimulation, the current, 1.5 mA, will be delivered for a short amount of time and then turn-off. To deliver the current, electrodes that are placed in saline soaked sponges. They will be attached to the left side of your head; they will be held in place with an elastic cap. For both real and sham stimulation the electrodes will be placed on the scalp. Most people cannot tell the difference between real and sham stimulation.
Study: NCT00432575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT00581256

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D
Description: All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
Study: NCT01196104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Usual Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Study: NCT02478086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use amine acids parenteral 3.5g
Description: Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: use amine acids parenteral 4g
Description: Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet.